-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Y-mAbs Therapeutics (YMAB) receives FDA CRL for omburtamab
-
-
-
-
-
-
-
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab
-
-
-
-
15,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

